Back to Industry News
Medtech
Arjo's Q3 Falls Short Despite Strong Demand and Growth Initiatives
Summary generated with AI, editor-reviewed
Heartspace News Desk
•Source: Medtech Magazine, Medtech Magazine
Photo by Navy Medicine on Unsplash
TL;DR
Arjo's third-quarter results missed analyst expectations due to lower-than-anticipated organic growth of 3.8 percent and failure to meet adjusted EBITDA targets. However, acting CEO Niclas Sjöswärd noted growth in most markets, a significant rise in adjusted operating profit, and the successful launch of the Maxi Move 5 floor lift with over 600 units sold.
Stay updated on stories like this
Key takeaways
- Arjo's third-quarter results fell short of analyst expectations, according to a report in Medtech Magazine, despite consistent demand for the company's medical technology solutions
- The company reported organic growth of 3
- 8 percent, underperforming the anticipated 5
Arjo's third-quarter results fell short of analyst expectations, according to a report in Medtech Magazine, despite consistent demand for the company's medical technology solutions. The company reported organic growth of 3.8 percent, underperforming the anticipated 5.1 percent. Adjusted EBITDA also did not meet projected targets.
Acting CEO Niclas Sjöswärd highlighted positive developments, including growth across most markets and a significant increase of over 20 percent in adjusted operating profit, excluding currency and tariff impacts. He also cited the successful launch of the Maxi Move 5 floor lift, with over 600 units sold, as a key achievement.
Related Topics
Arjofinancial resultsmedical technologygrowthEBITDA
Never miss stories like this
Verified mention available
Free to claim
Is this your company?
Set up real-time alerts and keep your Heartspace News coverage accurate. Verified teams can update profiles, request corrections, and collaborate on future stories.
Set up alerts Takes under 1 minute • Verified manually